サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1526192

中枢神経系治療薬の世界市場

CNS Therapeutics

出版日
ページ情報
英文 898 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
中枢神経系治療薬の世界市場
出版日: 2024年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 898 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

中枢神経系治療薬の世界市場は2030年までに1,990億米ドルに達する見込み

2023年に1,220億米ドルと推定される中枢神経系治療薬の世界市場は、2023年から2030年にかけてCAGR 7.2%で成長し、2030年には1,990億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである神経変性疾患治療薬は、CAGR 7.9%を記録し、分析期間終了時には759億米ドルに達すると予測されます。メンタルヘルス治療薬セグメントの成長率は、分析期間中CAGR 7.0%と推定されます。

米国市場は492億米ドルと推定、中国はCAGR 11.3％で成長予測

米国の中枢神経系治療薬市場は2023年に492億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに199億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは11.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.5％と6.4％と予測されています。欧州では、ドイツがCAGR約6.2%で成長すると予測されています。

世界の中枢神経系治療薬市場- 主要動向と促進要因まとめ

中枢神経系（CNS）治療薬には、脳や脊髄の障害や疾患への対処を目的とした幅広い治療が含まれます。これには、アルツハイマー病、パーキンソン病、てんかん、うつ病、多発性硬化症などの疾患が含まれます。中枢神経系治療薬は、医薬品、生物学的製剤、遺伝子治療や細胞治療のような先進治療から構成されます。中枢神経系と血液脳関門は複雑であるため、効果的な治療法の開発には大きな課題があるが、神経科学、分子生物学、ドラッグデリバリーシステムの進歩により、革新的な治療アプローチが生まれつつあります。精密医療と個別化治療は中枢神経系治療薬においてますます重要性を増しており、より的を絞った効果的な介入の可能性を提供しています。

中枢神経系治療薬の市場を牽引しているのは、神経疾患や精神疾患の高い有病率であり、これらは世界中の生活の質やヘルスケアシステムに大きな影響を与えています。人口の高齢化は、アルツハイマー病やパーキンソン病などの神経変性疾患の罹患率上昇に寄与しています。さらに、認知度の向上と診断能力の向上により、中枢神経系疾患の早期発見と治療が進んでいます。製薬業界は中枢神経系の研究開発に多額の投資を行っており、その結果、新薬や治療薬のパイプラインが充実しています。また、規制当局も中枢神経系疾患に対する革新的な治療法の認可を優先しており、効果的な解決策が急務であることを認識しています。

中枢神経系治療薬市場の成長は、いくつかの要因によって牽引されています。第一に、人口の高齢化と診断技術の向上による神経疾患および精神疾患の有病率の増加が、中枢神経系治療に対する需要を押し上げています。第二に、神経科学研究と医薬品開発の著しい進歩が、より効果的な新たな治療選択肢を生み出しています。第三に、精密医療と個別化治療が重視されるようになり、治療効果と患者の転帰が向上しています。最後に、支持的な規制環境と中枢神経系疾患治療の優先順位付けにより、新しい治療法の承認と商業化が加速しています。これらの要因が総合的に、中枢神経系治療薬市場のダイナミックな成長に寄与しています。

調査対象企業の例（全353件）

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Acumen Pharmaceuticals, Inc.
  • Alexza Pharmaceuticals
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AC Immune SA
  • Addex Therapeutics
  • Ache Laboratorios Farmaceuticos SA
  • 4D pharma plc
  • Acadia Pharmaceuticals, Inc.
  • AB Science SA
  • ABL Bio, Inc.
  • AcelRx Pharmaceuticals
  • Aarti Drugs Ltd.
  • Abion

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 治療カテゴリー別市場分析
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-1835

Global CNS Therapeutics Market to Reach US$199.0 Billion by 2030

The global market for CNS Therapeutics estimated at US$122.0 Billion in the year 2023, is expected to reach US$199.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. Neurodegenerative Diseases Therapeutics, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$75.9 Billion by the end of the analysis period. Growth in the Mental Health Therapeutics segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$49.2 Billion While China is Forecast to Grow at 11.3% CAGR

The CNS Therapeutics market in the U.S. is estimated at US$49.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$19.9 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global CNS Therapeutics Market - Key Trends & Drivers Summarized

Central Nervous System (CNS) therapeutics encompass a broad range of treatments aimed at addressing disorders and diseases of the brain and spinal cord. These include conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, depression, and multiple sclerosis. CNS therapeutics comprise pharmaceuticals, biologics, and advanced therapies like gene and cell therapies. The complexity of the CNS and the blood-brain barrier poses significant challenges in developing effective treatments, but advances in neuroscience, molecular biology, and drug delivery systems are leading to innovative therapeutic approaches. Precision medicine and personalized treatments are becoming increasingly important in CNS therapeutics, offering the potential for more targeted and effective interventions.

The market for CNS therapeutics is driven by the high prevalence of neurological and psychiatric disorders, which significantly impact the quality of life and healthcare systems worldwide. An aging population is contributing to the rising incidence of neurodegenerative diseases like Alzheimer's and Parkinson's. Additionally, increased awareness and better diagnostic capabilities are leading to earlier detection and treatment of CNS conditions. The pharmaceutical industry is heavily invested in CNS research and development, resulting in a robust pipeline of new drugs and therapies. Regulatory agencies are also prioritizing the approval of innovative treatments for CNS disorders, recognizing the urgent need for effective solutions.

The growth in the CNS therapeutics market is driven by several factors. Firstly, the increasing prevalence of neurological and psychiatric disorders due to aging populations and improved diagnostics is boosting demand for CNS treatments. Secondly, significant advancements in neuroscience research and drug development are leading to new and more effective therapeutic options. Thirdly, the growing emphasis on precision medicine and personalized therapies is enhancing treatment efficacy and patient outcomes. Lastly, supportive regulatory environments and the prioritization of CNS disorder treatments are accelerating the approval and commercialization of new therapies. These factors collectively contribute to the dynamic growth of the CNS therapeutics market.

Select Competitors (Total 353 Featured) -

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Acumen Pharmaceuticals, Inc.
  • Alexza Pharmaceuticals
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AC Immune SA
  • Addex Therapeutics
  • Ache Laboratorios Farmaceuticos SA
  • 4D pharma plc
  • Acadia Pharmaceuticals, Inc.
  • AB Science SA
  • ABL Bio, Inc.
  • AcelRx Pharmaceuticals
  • Aarti Drugs Ltd.
  • Abion

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Central Nervous System (CNS) Therapeutics: A Prelude
    • Global Central Nervous System Therapeutic Market Glimmers with Robust Health
    • Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
    • Developed Markets to Maintain their Dominance
    • Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth
    • Neurodegenerative Disease & Mental Health: Lifeline Segments of CNS Therapeutics Market
    • CNS Cancer Segment to Post Fastest Growth
    • Competition
    • CNS Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Recent Market Activity
  • MARKET ANALYSIS BY THERAPEUTIC CATEGORY
    • Anti-Epilepsy Market
    • Regional Landscape
    • Developed Countries Account for a Major Share of Epilepsy Treatment
    • Developing Countries Struggle with Low Treatment Rates
    • Disease Overview
    • Epilepsy Incidence by Type (2022E): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
    • Symptomatic Epilepsy Incidence by Type (2022E): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
    • Global Epilepsy Etiology: Percentage Breakdown by Type for 2022E
    • Drugs for Epilepsy
    • Market for Epilepsy Drugs
    • Regional Landscape
    • Developing Countries Struggle with Low Treatment Rates
    • High Unmet Needs Offer Scope for Market Growth
    • Treatment
    • Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
    • Leading Anti-Epileptic Drugs
    • Leading Anti-Epileptic Drugs and Their Mechanism of Action
    • Patent Expiries of Major Anti-Epilepsy Drugs
    • FDA's New Policy for AED Drugs to Bolster Market Growth
    • AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
    • Select Currently Available Epilepsy Drugs
    • Innovative Drugs Needed for Better Treatment Compliance
    • Abounding Potential for NCEs
    • A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
    • FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
    • Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
    • Recent Approvals for Childhood Epilepsy
    • Review of Anti-Epilepsy Drugs
    • Vimpat(R)
    • Keppra(R)
    • Lamictal
    • Tegretol(R)
    • Sabril(R)
    • Perampanel
    • Zonegran(R)
    • Topamax(R)
    • Trileptal(R)
    • Neurontin(R)
    • Lyrica(R)
    • Depakine(R)
    • Anti-Alzheimer's
    • Market Overview
    • Global Alzheimer's Prevalence by Age Group
    • Alzheimer's Phase III Completed Studies
    • Alzheimer's Phase III Ongoing Studies
    • Treatment for Alzheimer's
    • Select Leading Drugs for Alzheimer's Disease by Drug Category
    • Patent Expiries of Leading Alzheimer's Drugs
    • Alzheimer's Drugs: A Market Plagued with Failures
    • Promising Compounds with Silver Lining
    • Updated FDA Standards Make Way for Increased Alzheimer's Drug Testing
    • Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
    • Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
    • Novel Drug Delivery Method to the Brain Discovered
    • Alzheimer's Association Provides Grant to Longeveron
    • A Review of Select Anti-Alzheimer's Drugs
    • Aricept
    • Exelon
    • Reminyl
    • Ebixa
    • Namenda
    • A Review of the Alzheimer's disease
    • Alzheimer's Effect on Brain
    • Causes for Alzheimer's
    • Who Are at Risk?
    • Prevalence of Alzheimer's Disease
    • Diagnosis of Alzheimer's
    • Anti-Parkinson's
    • Market Overview
    • Nourianz, An Add-on Medication for Treating Episodes of Parkinson's Disease Secures FDA Approval
    • Recent Approvals
    • Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
    • Xadago - Add-On Therapy for Parkinson's Disease
    • NUPLAZID(R) - The First and the Only Approved Drug for Psychosis related to Parkinson's disease
    • Select Parkinson's Phase III Completed Studies: As of June 2022
    • Select Parkinson's Ongoing Phase III Studies: As of June 2022
    • Select Anti-Parkinson's Drugs
    • Levodopa
    • Dopamine Agonists
    • Mirapex
    • GSK Discontinues Requip for PD and RSL Treatment
    • A Review of the Parkinson's Disease
    • Prevalence
    • Symptoms
    • Causes
    • Diagnosis
    • Anti-Depressants
    • Market Overview
    • Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
    • Anti-Depressant Treatment
    • Select Antidepressants Drugs
    • Zoloft (Sertraline)
    • Cymbalta(R)
    • Prozac (Fluoxetine)
    • Effexor (Venlafaxine)
    • Paxil
    • Wellbutrin (Bupropion)
    • Select Pipeline Drugs in Phase III for Depressive Disorders: As of June 2022
    • A Review of Depression
    • Prevalence of Depression
    • Causes of Depression
    • Types of Depressive Disorders
    • Available Treatment
    • Tricyclic Antidepressants
    • Monoamine Oxidase Inhibitors
    • Lithium Salts
    • Working of Antidepressants
    • Ranking of Antidepressants in Terms of Efficacy
    • Types of Antidepressants
    • NMDA Receptor Antagonists
    • NMDA Receptor (NMDAR)
    • NMDA Receptor Agonists
    • Acetylcholinesterase Inhibitors
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Workings of SSRIs
    • Safety Levels of SSRI Drugs
    • Adverse Effects of SSRI
    • Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
    • Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
    • Multiple Sclerosis (MS)
    • List of Approved Drugs for MS
    • Patent Expiration Date/Year of the Major MS Drugs
    • New Approvals
    • Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
    • Mavenclad Gains FDA Approval
    • Celgene Files NDA for Ozanimod
    • Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
    • Multiple Sclerosis: Pipeline Analysis
    • Select Pipeline Drugs in Phase III for Multiple Sclerosis: As of June 2022
    • A Review of Multiple Sclerosis (MS)
    • Types of Multiple Sclerosis
    • Clinical Subtypes of Multiple Sclerosis (MS)
    • Prevalence of MS
    • Causes of MS
    • Myths Surrounding Multiple Sclerosis
    • Symptoms of MS
    • Diagnosis of MS
    • Insomnia
    • Overview
    • List of Approved Drugs for Insomnia
    • Select Pipeline Drugs for Insomnia: As of June 2022
    • Zolpidem
    • Eszopiclone
    • A Review of Insomnia
    • Prevalence of Insomnia
    • Therapies for Insomnia
    • CNS Pain Management
    • Market Overview
    • Treatment
    • Drugs Indicated for Pain Management
    • Regional Overview
    • Players
    • Combination Therapies Gain Prominence
    • Key Trends in Chronic Pain Management
    • Neuropathic Pain Management: Market with High Potential
    • Select Phase III Ongoing Studies for Neuropathic Pain
    • Lyrica's Generics Gain FDA Approval
    • Migraine Market: A Core Vertical in CNS Pain Management
    • Migraine Care: Select Patent Expiries (2013-2015)
    • Migraine Completed Phase III Studies
    • Migraine Ongoing Phase III Studies
    • Select Pain Management Drugs
    • Flupirtine
    • Lyrica
    • Oxycodone
    • Nucynta ER
    • Metabotropic Glutamate Receptors (mGluRs)
    • New Pain Management Drugs
    • Novartis Presents New Data for Aimovig
    • Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
    • Three New Migraine Drugs Obtain FDA Approval
    • Eli Lilly's Emgality Receives FDA Approval
    • An Insight into Mental Health Prevalence and Addressal
    • Global Prevalence of Mental Health Disorders by Type
    • Anti-Psychotics
    • Market Overview
    • Leading Atypical Antipsychotics for the Treatment of Schizophrenia
    • Select Pipeline Drugs in Phase III for Schizophrenia: As of June 2022
    • Select Pipeline Drugs in Phase III for Bipolar Disorder: As of June 2022
    • Select Anti-Psychotic Drugs
    • Zyprexa
    • Seroquel
    • Abilify
    • Clozaril
    • Risperdal
    • Risperdal(R) Consta(R)
    • Geodon
    • Invega Sustenna
    • Saphris
    • Latuda
    • A Review of Anti-Psychotics
    • Indications of Antipsychotics
    • An Effective Adjunctive Therapy
    • Off-label Uses
    • Efficacy - Marred by Lack of Evidence Base
    • Types of Antipsychotics
    • Difference between Typical and Atypical
    • Atypical Antipsychotics Up Against Typicals
    • Side Effects of Antipsychotics
    • Symptoms of Antipsychotics Withdrawal
    • Bipolar Disorder
    • Symptoms of Bipolar Disorder
    • Mood Episode - A Major Symptom
    • Manic Episode Vs Depressive Episode
    • Causes of Bipolar Disorder
    • Types of Bipolar Disorder
    • Co-morbidities of Bipolar Disorder
    • Schizophrenia
    • Prevalence by Gender
    • Symptoms of Schizophrenia
    • Causes of Schizophrenia
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Neurodegenerative Conditions
    • Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
    • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
    • Rising Healthcare Expenditure to Boost CNS Therapeutics Market
    • World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
    • Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
    • Growing Middle Class Population in Emerging Regions to Spur the Market
    • Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
    • Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
    • Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
    • Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
    • Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
    • Awareness Campaigns Launched by Pharma Companies to Benefit the Market...
    • Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
    • New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines
    • Influx of New Products & Strong Pipeline
    • CNS Pharmaceuticals Secures FDA Approval for Protocol Amendment to Trial Targeting GBM Treatment
    • Central Nervous System Therapeutics: From Bleak to Bright Outlook
    • Novel Drug-Delivery Options
    • Advances in Drug Discovery Methods for Rare Diseases
    • Market Restraint: Complex Nature of R&D
    • Ongoing Research on Psychedelics Substances Pave Way for Ensuring Timely Treatment for Various Mental Illnesses
    • Advent of Advanced Disease Pathology and Diagnostics Techniques Facilitate Medical Professionals in Diagnosing Mental Illness at an Earlier Stage
    • Introduction of Innovative Technologies Fuel Demand for Biological Medicines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World CNS Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Mental Health by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Neurovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Cns Trauma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Cns Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Market Facts & Figures
    • Aging Population: A Strong Demographic Driver
    • North American Elderly Population by Age Group (1975-2050)
    • The Largest CNS Therapeutics Market Globally
    • Patent Expiries of Leading CNS Drugs in the US
    • Focus on Select Markets
    • Alzheimer's Market
    • Anti-depressant Drugs
    • Usage of Antidepressants Surges in the US
    • Anti-Epilepsy Market
    • Epilepsy - A Major Concern for the Healthcare Industry
    • A Glance at Epilepsy Statistics
    • Anti-Epilepsy Drugs
    • The US Epilepsy Market: Patent Expiry of Select Major Drugs
    • Epilepsy in Children
    • Growing Competition from Generics
    • Pain Management Market
    • Consumers in the US Seek Different Options for Chronic Pain Management
    • Neuropathic Pain Market
    • Anti-Psychotic Drugs Market
    • Mental Illnesses - Epidemiology
    • Facts & Figures
    • Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
    • Popular Antipsychotic Drugs in the US
    • The US Anti-Psychotic Drugs Market by Indication (2022E): Percentage Share Breakdown of Value Sales
    • Surging Off-label Prescriptions
    • Generics Occupy Front Seat
    • Rising Antipsychotic Use among Children - A Cause of Concern
    • Market Analytics
    • Market Analytics
    • TABLE 26: USA Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • CANADA
    • CNS Diseases: Facts & Figures
    • TABLE 29: Canada Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • JAPAN
    • TABLE 32: Japan Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • CHINA
    • China: The Primary Market for CNS Drugs in Asia-Pacific
    • Select Anti-Schizophrenia Drugs Available in China
    • Other Available CNS Drugs in China
    • TABLE 35: China Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • EUROPE
    • Market Facts & Figures
    • Pain Management Market
    • Neuropathic Pain Market Witnesses Foray of Generics
    • Anti-Psychotics Market
    • Demand for Antipsychotics for Bipolar Disorder Upbeat
    • Market Analytics
    • TABLE 38: Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • FRANCE
    • TABLE 44: France Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: France Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: France 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • GERMANY
    • TABLE 47: Germany Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Germany 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • ITALY
    • Market Snapshots
    • TABLE 50: Italy Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Italy 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • NICE Recommendations on CNS Therapeutics
    • TABLE 53: UK Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: UK 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Spain Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Spain 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 59: Russia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Russia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Russia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Rest of Europe Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Rest of Europe 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • India & China Offer Significant Growth Opportunities
    • Growing Antipsychotics Market in Asia
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Asia-Pacific 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • TABLE 71: Australia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Australia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Australia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • INDIA
    • TABLE 74: India Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: India Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: India 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 77: South Korea Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: South Korea Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: South Korea 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Asia-Pacific Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Asia-Pacific 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Latin America Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Latin America 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 89: Argentina Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Argentina Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Argentina 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 92: Brazil Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Brazil Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Brazil 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 95: Mexico Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Mexico Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Mexico 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Latin America Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Latin America 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 104: Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Middle East Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Middle East 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 107: Iran Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Iran Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Iran 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 110: Israel Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Israel Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Israel 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Saudi Arabia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Saudi Arabia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 116: UAE Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UAE Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UAE 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Middle East Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Middle East 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
  • AFRICA
    • TABLE 122: Africa Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Africa Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Africa 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030

IV. COMPETITION